The Silent Epidemic: Kratom Use, Emerging Derivatives, and the Growing Risk Across Florida, Georgia, and Texas 

04/13/2026 | DevotedDOc | , ,

For years, the clinical community has watched from the sidelines as kratom (Mitragyna speciosa) occupied a convenient, yet dangerous, regulatory “gray zone.” Marketed as a “natural supplement” and a “safe” herbal alternative for pain management or opioid withdrawal, the reality on the ground in our Emergency Departments and addiction clinics has shifted. We are no longer dealing with a simple Southeast Asian leaf. We are witnessing the evolution of a pharmacologically potent, semi-synthetic drug category that is currently outpacing our public health surveillance and clinical screening capabilities.

As a physician in the trenches of clinical care, I see the fallout of this “natural” remedy daily. When patients present with unexplained withdrawal syndrome that mirrors high-dose oxycodone, they often don’t even think to mention their “herbal tea.” This is the hallmark of a silent epidemic: a crisis that is legal, accessible, and virtually invisible to standard toxicology screens.

The Magnitude of the Surge: What the CDC Data Actually Shows

The most definitive evidence of this crisis comes from the Centers for Disease Control and Prevention (CDC). According to the March 2026 MMWR report, “Increases in Kratom-Related Reports to Poison Centers — National Poison Data System, United States, 2015–2025,” the trajectory is staggering. Analysis of the National Poison Data System (NPDS) found an increase of approximately 1,200% in kratom-related exposure reports over the last decade.

In 2015, there were a mere 258 reports nationwide. By 2025, that number surged to a record high of 3,434 reports. During the 11-year study period, poison centers documented a total of 14,449 kratom exposures. While the highest volume of reports involves young adults aged 20–39, the CDC notes that reports among adults aged 40–59 increased most sharply, with rates nearly overlapping those of younger populations by 2025.

Critically, the CDC data highlights a “marked surge” specifically in 2025. This spike is not a coincidence; it aligns perfectly with the emergence of high-potency, semi-synthetic formulations that have moved far beyond the traditional Kratom leaf.

The Evolution of Kratom: From Leaf to Semi-Synthetic Opioid

The narrative that kratom is just a “relative of the coffee plant” is a dangerous reductionism. While the primary alkaloid in the plant is mitragynine, the real emerging threat lies in its derivatives—specifically 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MP).

In traditional, dried kratom leaves, 7-OH exists only in trace amounts, typically less than 0.05% to 2% of the total alkaloid content. However, the commercial market has pivoted to concentrated extracts where 7-OH levels can reach 98% of the total alkaloid fraction. This is no longer a botanical product; it is a laboratory-fortified opioid.

The Potency Problem

The pharmacology of these derivatives is alarming:

  • 7-hydroxymitragynine (7-OH): Research cited by NIDA and the CDC indicates that 7-OH is up to 13 times more potent than morphine at the mu-opioid receptor.
  • Mitragynine Pseudoindoxyl (MP): A rearrangement product of 7-OH that has recently emerged in consumer markets. MP is reported to be even more potent than 7-OH, with some studies suggesting its affinity for opioid receptors is nearly as potent as fentanyl.

These compounds bypass the natural metabolic formation in the liver and provide immediate, high-affinity binding to the brain’s opioid receptors. This results in rapid tolerance, profound physical dependence, and a withdrawal syndrome that clinicians are finding increasingly difficult to manage with standard protocols.

Why Multi-Substance Use is the Real Driver of Mortality

The “silent” nature of this epidemic is most lethal when kratom is combined with other substances. The CDC report clarifies that while single-substance kratom reports accounted for 62% of the total, multiple-substance reports occurred at higher rates and were associated with significantly more hospitalizations.

The annual percentage of hospitalizations was consistently higher among persons with multiple-substance exposure reports (44%–56%) than among those using kratom alone (24%–29%). According to the NPDS data, the most common substances involved in these high-risk combinations include:

  • Ethanol (22%)
  • Opioids (16%)
  • Benzodiazepines (15%)
  • Antidepressants (14%)
  • Cannabinoids (12%)

From a clinical perspective, this is a “polypharmacy toxicity” nightmare. Combining a potent mu-opioid receptor agonist like 7-OH with CNS depressants like alcohol or benzodiazepines creates a synergistic effect. We are seeing ICU-level emergencies because patients assume that because they bought the product at a gas station in Florida or Texas, it cannot possibly be as dangerous as a prescription pill.

Clinical Perspective: Dr. Matthew Berrios on the “Vulnerability Window”

In the Emergency Department and clinic, we are often the first to see the “vulnerability window” where a patient’s self-treatment with kratom turns into a medical emergency. One of the most significant clinical hurdles is that standard 5-panel or 10-panel drug tests do not detect mitragynine or 7-OH. Unless a physician has a high index of suspicion and orders a specialized liquid chromatography-tandem mass spectrometry (LC-MS-MS) screen, the diagnosis is missed.

When patients present with “unexplained” toxidromes—pinpoint pupils, bradycardia, or respiratory depression—and their standard tox screen comes back negative, kratom must be at the top of the differential diagnosis. We are also seeing a rise in kratom-associated seizures, a side effect rarely seen with traditional opioids but increasingly common with high-potency extracts and multi-substance use involving stimulants or antidepressants.

Public Safety and the Regulatory Gap: Mike Alvarez on the “Gas Station High”

From a policy and public safety standpoint, the proliferation of kratom is a failure of infrastructure. In states like Georgia and Texas, kratom has become the premier “gas station drug,” often sold right next to hemp-derived THC products.

As Mike Alvarez, MPA, notes, the regulatory landscape is a patchwork of “Consumer Protection Acts” that vary wildly by state, leaving huge gaps for bad actors. Manufacturers frequently engage in misleading labeling, hiding the presence of semi-synthetic 7-OH under the guise of “natural kratom.” This is not just a health issue; it is a consumer fraud issue that is killing people. The current “whack-a-mole” approach to regulation where a state bans one derivative only for a slightly modified version to appear weeks later is insufficient to protect the public.

Regional Battlegrounds: Florida, Georgia, and Texas

The risk profile for kratom use is particularly acute in the Southern U.S., where access is high and regulation is in flux.

In Florida, the situation is complex. While Sarasota County banned kratom years ago labeling it a “designer drug,” it remains legal statewide. In 2023, the legislature enacted the Florida Kratom Consumer Protection Act, which ostensibly prohibits sales to those under 21. However, the real battle is over 7-OH. In August 2025, Florida’s Attorney General implemented an emergency rule to remove dangerous 7-OH products from shelves, but recent reporting from March 2026 indicates that lawmakers have not finalized a permanent ban before the session ended. This means 7-OH could return to Florida shelves as early as June 2026, creating a significant public health risk if not addressed. 

Kratom Georgia: Strict Limits and Tragic Precedents

Georgia has taken a more aggressive stance, largely driven by the accidental overdose death of 23-year-old Ethan Pope in Cobb County. The state’s updated Kratom Consumer Protection Act (effective January 2025) prohibits the sale of any product with a concentration greater than 0.5 mg of 7-OH per gram or 1 mg per serving. Georgia has also banned the ingestion of kratom via heating elements (vaping), acknowledging the rapid-onset risks associated with inhalation of alkaloids. Despite these rules, kratom withdrawal in Georgia remains a common clinical complaint, as the availability of “legal” doses still facilitates significant physical dependence.

Kratom Texas: AG Lawsuits and Potency Extremes

Texas is currently a primary theater for the 7-OH crisis. Texas Attorney General Ken Paxton recently sued retailers for selling kratom products containing nearly fifty times the legal limit of 7-OH. Investigations revealed products with 7-OH levels ranging from 86% to 96% of total alkaloid content, far exceeding the 2% maximum allowed under the Texas Kratom Consumer Health and Safety Protection Act. For those seeking kratom addiction treatment in Texas, the clinical challenge is that these patients aren’t just coming off a plant; they are coming off a substance that is, in practice, a high-dose synthetic opioid.

The Mental Health Overlap: Suicide and Antidepressants

One of the most sobering findings in the CDC’s 2026 MMWR report is the link between kratom and mental health crises. Suspected suicide attempts were significantly more frequent among multiple-substance kratom reports (23%) than single-substance reports (6%).

Furthermore, antidepressants were involved in 14% of all multi-substance kratom exposures. This suggests that individuals with underlying depression or anxiety are turning to kratom for self-medication, only to experience “psychiatric destabilization” when the potent alkaloids interact with their prescribed medications or when they enter a withdrawal state.

Clinical Implications: Screening, Risk Stratification, and Treatment

The healthcare system is currently behind the curve in identifying and treating kratom-related risk. To close this gap, we must implement three core strategies:

Clinicians must move beyond the standard “Do you use drugs?” question. In Florida, Georgia, and Texas, we must specifically ask patients about kratom, “herbal shots,” and “gas station gummies.” This is especially critical for patients presenting with chronic pain, anxiety, or unexplained neurological symptoms.

2. Risk Stratification

Not all kratom use is equal. A patient using traditional leaf powder for energy is at a different risk level than a patient using concentrated 7-OH tablets. We must differentiate between botanical use and the use of semi-synthetic derivatives, as the latter requires a much more intensive clinical intervention.

3. Evidence-Based Withdrawal Management

Because kratom alkaloids target the mu-opioid receptor, buprenorphine (Suboxone) has emerged as a highly effective tool for managing withdrawal and cravings in those with a past history of opioid use disorder.

  • Low-dose users (<20g daily): Often successfully initiated on 4/1 mg to 8/2 mg of buprenorphine-naloxone.
  • High-dose users (>40g daily or 7-OH users): May require 12/3 mg to 16/4 mg for initial stabilization.
    At DevotedDOC, our telehealth addiction specialists utilize these precise, physician-led protocols to provide rapid relief for patients in the Southern U.S. who are trapped in the cycle of kratom dependence.

Why This is a “Silent Epidemic”

Kratom remains a silent epidemic because it thrives in the darkness of clinical ignorance and regulatory inertia.

  • It is Legal: Legality is often confused with safety. The “natural” label provides a false sense of security.
  • It is Accessible: As long as these products are sold in convenience stores, the barrier to entry for youth and vulnerable populations is effectively zero.
  • It is Under-Reported: The CDC notes that the 1,200% increase is likely an underestimate, as many individuals are unaware that their “supplement” is the cause of their symptoms.

The Future: Derivatives, Regulation, and Surveillance

The future of this crisis will be defined by our ability to keep pace with the laboratory. 7-hydroxymitragynine is just the beginning. We are already seeing the emergence of mitragynine pseudoindoxyl and other analogs that are designed to evade current laws.

Federal and state governments must move toward a unified regulatory framework that treats high-potency kratom extracts for what they are: controlled substances. We also need to integrate mitragynine into standard hospital toxicology panels to provide real-time data on the prevalence of this substance in our communities.

Conclusion: A Physician-Led Call to Action

The 1,200% increase in kratom poisonings reported by the CDC is a siren in the night. We can no longer treat kratom as a harmless botanical curiosity. In Florida, Georgia, and Texas, the “natural supplement” mask has slipped, revealing a powerful opioid-like threat that is devastating families and overwhelming our emergency systems.

As a physician-led organization, DevotedDOc is committed to bringing this epidemic into the light. We provide the clinical infrastructure and the expertise in addiction medicine necessary to identify, treat, and overcome kratom dependence. The epidemic may be silent, but the path to recovery must be clear and authoritative.

References and Clinical Data Sources:

If you or someone you know is struggling with kratom use or withdrawal in Florida, Georgia, or Texas, consult with a physician addiction specialist immediately. Rapid, telehealth-based treatment is available.

Share this post:

Recent Posts

Categories